GENFIT Unveils Provisional Financial Calendar for 2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical leader in addressing rare and life-threatening liver diseases, has officially announced its provisional financial calendar for 2026. The calendar details critical dates for revenue publications and financial statements, reflecting GENFIT's ongoing commitment to transparency and investor communication.
Key Dates in GENFIT's 2026 Financial Calendar
- February 26, 2026: Publication of revenue and cash position as of December 31, 2025.
- April 2, 2026: Full Year 2025 financial statements release.
- May 21, 2026: Publication of revenue and cash position as of March 31, 2026.
- June 15, 2026: Annual Shareholders Meeting.
- September 29, 2026: Publication of the half-year 2026 financial statements.
- November 5, 2026: Publication of revenue and cash position as of September 30, 2026.
Please note that this calendar is subject to change.
About GENFIT
GENFIT is a pioneering biopharmaceutical company that focuses on developing solutions for patients afflicted by rare liver diseases, where medical needs remain largely unmet. With a strong scientific background built over two decades, GENFIT specializes in Acute on-chronic Liver Failure (ACLF) and conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). The company is committed to addressing critical pathophysiological mechanisms through its therapeutic assets.
Moreover, GENFIT is also targeting serious diseases including cholangiocarcinoma (CCA), urea cycle disorders (UCD), and organic acidemia (OA). The company's extensive R&D portfolio ensures a steady flow of news related to their advancements.
Recent Developments and Products
In 2024, GNFT marked a significant milestone with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for treating Primary Biliary Cholangitis (PBC). This treatment is now available in multiple countries.
Apart from therapeutic developments, GENFIT also has a diagnostic franchise featuring NIS2+®, designed for detecting Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH).
Company Background and Corporate Structure
Founded in Lille, France, GENFIT has additional offices in Paris, Zurich, and Cambridge, MA, USA. The company is committed to social responsibility, as evidenced by its BCorp™ certification obtained in 2025. Listed on the Euronext regulated market in Paris (Compartment B, Euronext: GNFT), GENFIT has garnered significant interest from investors, including Ipsen, which acquired an 8% stake in the company's capital in 2021.
Forward-Looking Statements
This announcement contains forward-looking statements in accordance with the Private Securities Litigation Reform Act of 1995. These statements may involve known and unknown risks and uncertainties that could cause actual results to differ significantly. Factors such as research and development uncertainties, trial progression, and regulatory approvals may impact the outcomes of GENFIT's operations. For a detailed understanding, please refer to the company’s public filings available on both GENFIT’s and the AMF's websites.
Contact Information
For investors, contact GENFIT at:
Tel: +33 3 2016 4000 | Email: investors@genfit.com
For media inquiries, contact:
Stephanie Boyer – Press relations
Tel: +33 3 2016 4000 | Email: stephanie.boyer@genfit.com
GENFIT’s headquarters: 885 Avenue Eugène Avinée, 59120 Loos, France. Visit us at www.genfit.com.